SignalCorporate
Gilead outlines ~$1.5B 2028 biktarvy revenue impact as 2026 base business guidance rises to $30.7B-$31.0B
Gilead cites ~$1.5B 2028 biktarvy revenue impact alongside raised 2026 base guidance of $30.7B-$31.0B.
Context
What happened: Gilead's Q3 2026 call covered raised 2026 base business guidance and the expected impact of CMS pricing on Biktarvy revenue in 2028.
Key numbers: 2026 base business guidance $30.7B to $31.0B, up $900M at midpoint vs August guidance.
Why it matters: Management said the CMS price does not reflect Biktarvy's value and expects total HIV revenue, total product sales, and EPS to grow in 2028 versus 2027 on other portfolio growth. Analysts focused on IRA mechanics, margins, and clinical holds.
Market: +4.0% today ($165.61), +37.0% YTD, 1.4x vol — as of 23:45 UTC
Verified: Q3_2026 (Oct 29) EPS $2.55 vs $2.19 est, +16.2% beat; next print ~Jan 28
Coverage: 4 outlets in 24h
What changed
Gilead's Q3 2026 call covered raised 2026 base business guidance and the expected impact of CMS pricing on Biktarvy revenue in 2028.
Why it matters
Management said the CMS price does not reflect Biktarvy's value and expects total HIV revenue, total product sales, and EPS to grow in 2028 versus 2027 on other portfolio growth. Analysts focused on IRA mechanics, margins, and clinical holds.
Market: +4.0% today ($165.61), +37.0% YTD, 1.4x vol — as of 23:45 UTC
Verified: Q3_2026 (Oct 29) EPS $2.55 vs $2.19 est, +16.2% beat; next print ~Jan 28